HCCA 2016 Orange County Regional Area Compliance Conference

June 17, 2016

Regulatory and Enforcement Update

Sara Kay Wheeler
King & Spalding

Goals of Session

- Explore Recent Enforcement and Regulatory Developments
- Analyze Provisions of Medicare Parts A and B final overpayment rulemaking
- Discuss strategies for addressing these fundamental changes, including investigation changes, governance considerations, and internal controls
- Questions
Important Developments

Landscape Continues to Intensify

• Several recent enforcement and regulatory developments have impacted the healthcare industry, including:
  — Enhanced OIG compliance program expectations and increased focus on individual accountability
  — Updated OIG Permissive Exclusion Criteria
  — DOJ Compliance Counsel
  — Yates Memo
  — Aggressive Relator Strategies
OIG’s Mounting Compliance Program Expectations

• Corporate Integrity Agreements (CIAs)
  — Agreement with HHS-OIG in connection with civil healthcare fraud settlement
  — Requires entity or individual to implement (or continue) certain integrity obligations for a period of years

Importance of CIA Trends to Non-CIA Obligated Providers

• OIG uses CIAs to communicate prudent approaches to compliance program design and compliance-related initiatives.
• Emerging trends in CIAs reflect OIG’s escalating compliance expectations for entities participating in federal healthcare programs.
• Why monitor and address emerging compliance trends?
  — Fortify compliance infrastructure
  — A company’s proactive efforts to monitor and address such emerging compliance trends often benefits the company when reviewed by Government enforcement agencies
Emerging CIA Trends

- Enhanced Board oversight
- Management’s responsibility for compliance
- Compliance Expert
- Active risk assessment and mitigation

Board Resolutions

1. Board of Directors: Compliant Obligations. The Board of Directors (or a committee of the Board) shall be responsible for the review and oversight of matters related to compliance with Federal health care program requirements and the obligations of the CIA. The Board (or a committee of the Board) must include independent (i.e., non-executive) members.

   a. meeting at least quarterly to review Compliance Program, including the performance of the Compliance Officer and the Compliance Committee;
   b. submitting to the CEO a description of any matters it reviews or recommends, in its exercise of the compliance function of reviewing and reporting on Federal health care program requirements and the obligations of the CIA.
   c. for each Fiscal Period of the CIA, prepare a report to the Board of Directors (or a committee of the Board) indicating the effectiveness of the Compliance Program, the adequacy of compliance with Federal health care program requirements and the obligations of the CIA.

   “The Board of Directors (or name of applicable committee of the Board) has made a reasonable inquiry into the operations of the Compliance Program including the performance of the Compliance Officer and the Compliance Committee. Based on its inquiry and review, the Board (or a committee of the Board) has concluded that, to the best of its knowledge, the Company has implemented an effective Compliance Program to meet Federal health care program requirements and the obligations of the CIA.”

At minimum, the resolution shall include the following language:

- Drafted by King & Spalding

KING & SPALDING
Enhanced Management Certifications

4. Management Certifications.

“I have been trained on and understand the compliance requirements and responsibilities as they relate to [insert name of department], an area under my supervision. My job responsibilities include ensuring compliance with regard to the [insert name of department] with all applicable Federal health care program requirements, obligations of the Corporate Integrity Agreement, and [insert policies]. I have taken steps to promote such compliance. To the best of my knowledge, except as otherwise described herein, the [insert name of department] is in compliance with all applicable Federal health care program requirements and the obligations of the Corporate Integrity Agreement. I understand that this certification is being provided to and relied upon by the United States.”

Retention of a Compliance Expert

3. Board of Directors: Corporate Compliance: The Board of Directors shall be responsible for reviewing and oversight of matters related to Federal health care program requirements and the obligations of the CIA. The Board must include independent members.

The Board shall, in addition, be responsible for the following:

a. By action at least quarterly to review and assess overall corporate compliance performance, including the steps taken to meet the obligations of the Compliance Officer and Corporate Compliance Committee.

b. Adopting written policies and procedures concerning federal health care program requirements and the obligations of the CIA, and the obligations of the CIA, and

c. For each Reporting Period of the CIA, adopting resolutions, signed by each member of the Board, approving the annual compliance program.

d. For the second and fourth Reporting Periods of the CIA, the Board shall retain an individual or entity with expertise in compliance with Federal health care program requirements (Compliance Expert) to perform a review of the effectiveness of the Compliance Program Review Report. The written report (Compliance Program Review Report) shall include a description of the Compliance Program Review and any recommendations with respect to the compliance program. The Board shall review the Compliance Program Review Report and shall provide a copy of the Compliance Program Review Report to the OIG in the Annual Report submitted for the second and fourth Reporting Periods by the Board. In addition, copies of any materials provided to the Board by the Compliance Expert, along with minutes of any meetings between the Compliance Expert and the Board, shall be made available to the OIG upon request.
Risk Assessment and Internal Review Process: Broad Scope

DOJ Compliance Counsel

• During the summer of 2015, DOJ revealed that it was hiring compliance counsel to assist DOJ prosecutors in assessing the effectiveness of companies’ corporate compliance programs.
  — Underscores increased importance on the effectiveness of corporate compliance programs.

• According to a DOJ representative, the compliance counsel will help prosecutors “differentiate the companies that get it and are trying to implement a good compliance program from the people who have a near-paper program.”
DOJ’s Assessment of Compliance Effectiveness

- Accordingly to recent remarks from Leslie Caldwell, DOJ will assess the effectiveness of compliance programs by asking questions such as:
  - Does the institution ensure that its directors and senior managers provide strong, explicit and visible support for its corporate compliance policies?
  - Do the people who are responsible for compliance have stature within the company?
  - Do compliance teams get adequate funding and access to necessary resources?
  - Are the institution’s compliance policies clear and in writing? Are they easily understood by employees?
  - Does the institution ensure that its compliance policies are effectively communicated to all employees? Are its written policies easy for employees to find?

DOJ’s Assessment of Compliance Effectiveness (Cont’d)

- Do employees have repeated training, which should include direction regarding what to do or with whom to consult when issues arise?
- Does the institution review its policies and practices to keep them up to date with evolving risks and circumstances?
- Are there mechanisms to enforce compliance policies? Those include both incentivizing good compliance and disciplining violations. Is discipline even handed?
- The department does not look favorably on situations in which low-level employees who may have engaged in misconduct are terminated, but the more senior people who either directed or deliberately turned a blind eye to the conduct suffer no consequences.
- Does the institution sensitize third parties like vendors, agents or consultants to the company’s expectation that its partners are also serious about compliance?
Yates Memorandum

• On September 9, 2015, Deputy Attorney General, Sally Quillian Yates, issued a memorandum (the Yates Memo) regarding individual accountability for corporate wrongdoing.
  — Provides guidance for both civil and criminal investigations.
• Emphasizes the need to hold individuals who perpetrated corporate wrongdoing accountable, “particularly in the aftermath of the financial crisis.”

Yates Memorandum

• In order to qualify for any cooperation credit, corporations must provide DOJ all relevant facts relating the individuals responsible for the misconduct.
  — Consider impact on internal investigations.
    — Potential revisions to Upjohn warning.
    — May dampen individuals’ willingness to be transparent with counsel.
Yates Memorandum

- Absent extraordinary circumstances, no corporate resolution will provide protection from criminal or civil liability for any individuals.

- Decision to bring suit against individuals should be based on considerations beyond the individual’s ability to pay.

UPHS Settlement

- The University of Pennsylvania Health System (UPHS) settled false claims allegations that UPHS billed Medicare for home health services that were not reasonable or necessary.

- Pursuant to the settlement agreement, UPHS agreed to pay approximately $75,000 and also agreed to ongoing compliance monitoring by the United States Attorneys’ Office (USAO) through 2019.

- As part of the ongoing monitoring, UPHS will be required to conduct semi-annual audits of home health claims and report the results to the USAO.

- USPHS is required to annually submit certified compliance reports to the USAO.
  - These reports must contain attestations by the USPHS billing compliance officer and the chief counsel. UPHS must also notify the USAO of any home health overpayments that are refunded.
Aggressive Relator Strategies

— Whistleblower cases continue to increase
— New relators, new relator’s counsel
  — Not just the disgruntled employee relator anymore
— Defense counsel must be prepared to defend litigation, not merely investigation
— Even if government declines to intervene, relator’s counsel continues case

OIG Permissive Exclusion Authority

• On April 18, 2016, OIG issued a revised policy statement containing the new criteria that OIG intends to use in implementing its permissive exclusion authority under 42 U.S.C.A. § 1320a-7(b)(7) (Revised Policy).

<table>
<thead>
<tr>
<th>Risk Spectrum</th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>Highest Risk</td>
<td>Lower Risk</td>
</tr>
</tbody>
</table>

Exclusion | Heightened Scrutiny | Integrity Obligations | No Further Action | Release (Self-Disclosure)
OIG Permissive Exclusion Authority

• Examples of Key Aspects of the Revised Policy
  — Compliance Program
    — The existence of a compliance program that incorporates the seven elements of an effective compliance program does not affect the risk assessment.
    — The absence of a compliance program that incorporates the seven elements of an effective compliance program indicates higher risk.
    — If the entity has devoted significantly more resources to the compliance function, this indicates lower risk.
  — History of Self Disclosures
    — If the person has a history, prior to becoming aware of the investigation, of significant self-disclosures made appropriately and in good faith to OIG, CMS (for Stark law disclosures), or CMS contractors (for non-fraud overpayments), this indicates lower risk.

OIG Permissive Exclusion Authority

• Examples of Key Aspects of the Revised Policy (cont’d)
  — Individual Accountability
    — In the case of an individual, if the individual organized, led, or planned the unlawful conduct, this indicates higher risk.
    — In the case of an entity, if individuals with managerial or operational control at or on behalf of the entity organized, led, or planned the unlawful activity, this indicates higher risk.
    — If the person’s cooperation resulted in criminal, civil, or administrative action or resolution with or against other individuals or entities, this further indicates lower risk.
  — Internal Investigations
    — If the person initiated an internal investigation before becoming aware of the Government’s investigation to determine who was responsible for the conduct, and shared the results of the internal investigation with the government, this indicates lower risk.
    — If the person self-disclosed the conduct cooperatively and in good faith as a result of the internal investigation, prior to becoming aware of the Government’s investigation, this indicates lower risk.
Recent Remarks from OIG Inspector General At HCCA Compliance Institute

- **Self-disclosure** is now the mark of an effective compliance program.
- **Self-correction** was specifically emphasized by Daniel Levinson as a pillar in the pursuit of the establishment of a strong healthcare institution.
- At its core, the 60-day overpayment rule is a combination of self-disclosure and self-correction.
The Affordable Care Act

- March 23, 2010: Enactment of the Affordable Care Act (ACA)

- Section 6402(a) of the ACA (now codified at 42 U.S.C. § 1320a-7k(d)):
  
  - A person who has received an overpayment must report and return the overpayment within either 60 days after the date on which the overpayment was identified or on the date any corresponding cost report is due, whichever is later.
  
  - The term “overpayment” means any Medicare or Medicaid funds that a person receives or retains to which the person, after applicable reconciliation, is not entitled.

Failure to report and return an overpayment can result in False Claims Act (FCA) and Civil Monetary Penalties (CMP) liability, as well as exclusion from participation in federal health care programs.
**Timeline of Significant Overpayment Developments**

- **March 2010**: Medicare Parts A/B Proposed Rule
- **February 2012**: Medicare Parts A/B Final Rule
- **January 2014**: Medicare Parts C/D Proposed Rule
- **May 2014**: Medicare Parts C/D Final Rule
- **February 2016**: No Medicaid Proposed Rule to date
- **April 2016**: ACA requirement for reporting and refunding Medicare and Medicaid overpayments enacted

**“Identification” Defined**

- **Medicare Parts A/B**: New regulatory definition in 42 C.F.R. § 401.305(a)(2)
  - An overpayment is identified “when the person has, or should have through the exercise of reasonable diligence, determined that the person has received an overpayment and quantified the amount of the overpayment.”

- **This definition includes two key concepts:**
  1. Concept of reasonable diligence
  2. Quantification
Concept of Reasonable Diligence

• The finalized definition of “identification” incorporates concept of “reasonable diligence.”
  • Guards against the “ostrich defense.”
• When does the 60-day clock begin to tick?
  1. When the exercise of reasonable diligence is completed, or
  2. If there is a failure to exercise reasonable diligence, on the day when the person received credible information of a potential overpayment.

• Important Observations:
  • A provider does not have to deplete its 60 days with efforts to quantify Medicare Parts A/B overpayments.
  • CMS also suspends the 60-day deadline for OIG Self-Disclosure Protocol or CMS Voluntary Self-Referral Disclosure Protocol submissions, at least until those submissions are resolved through settlement, withdrawal or removal.

Credible Information of Potential Overpayments

• Receipt of “credible information” triggers a duty to investigate.
  • “Credible information” is not specifically defined, but includes information that “supports a reasonable belief that an overpayment may have been received.”
  • Merriam-Webster definition of credible: “offering reasonable grounds for being believed.”
  • Merriam-Webster definition of information: “knowledge that you get about someone or something: facts or details about a subject.”
• CMS stated that it believes that “contractor overpayment determinations are always a credible source of information for other potential overpayments” and that “in certain cases, the conduct that serves as the basis for the contractor identified overpayment may be nearly identical to conduct in some additional time period not covered by the contractor audit.”
Exercise of Reasonable Diligence

- In the Medicare Parts A/B final rule, CMS states that absent “extraordinary circumstances,” a timely, good faith investigation of credible information will last at most six months from the receipt of the credible information.

- In Final A/B Rule, CMS stated that reasonable diligence includes both proactive compliance activities and reactive investigative activities.

Important Considerations:
- Size and scope of compliance programs will vary, but having no compliance activities may expose providers to liability.
- “Gray” area fact patterns – potential that even providers acting in good faith based on a reasonable interpretation of CMS’s requirements may become subject to second-guessing by an aggressive whistleblower or enforcement entity.

Quantifying a Potential Overpayment

- For Medicare Parts A/B, an overpayment is not “identified” until quantified (although there are time constraints for quantifying).

  - Prior to the issuance of the final Medicare Parts A/B rule, there was significant discussion in the industry regarding quantification issue.
  
  - Quantifying an overpayment can present numerous complexities and can involve significant effort.

    - Can use “statistical sampling, extrapolation methodologies and other methodologies as appropriate to determine the amount of the overpayment, rather than identifying every claim.”
    
    - Must explain in an overpayment report how the amount of the overpayment was calculated if statistical and extrapolation methods are used.
Parts A/B Overpayment Final Rule: Timeline

Final Rule’s General Timeframes for Reporting and Returning Medicare A and B Overpayments

<table>
<thead>
<tr>
<th>Event</th>
<th>Timeframe</th>
</tr>
</thead>
<tbody>
<tr>
<td>Receipt of “Credible Information” of a</td>
<td>No More than 6 Months to</td>
</tr>
<tr>
<td>Potential Overpayment</td>
<td>Investigate and Quantify</td>
</tr>
<tr>
<td></td>
<td>60 days to report and return the</td>
</tr>
<tr>
<td></td>
<td>Overpayments</td>
</tr>
<tr>
<td>Triggers Duty to Investigate</td>
<td></td>
</tr>
</tbody>
</table>

Unless “Extraordinary Circumstances,” No More Than 8 Months to Investigate and Report and Refund Medicare Parts A and B Overpayments

Lookback Period

- Pursuant to the Medicare Parts A/B Final Rule, Medicare Parts A/B overpayments must be reported and returned “only if a person identifies the overpayment within six years of the date the overpayment was received.”

- Maximum Threshold - providers should not be foreclosed from using a more limited lookback period if justified by the relevant circumstances (coverage change or EHR system conversion).

Practical challenges of lookback period:
- Recordkeeping difficulties
- Evolving regulatory standards
- Audit resources
- Potential need for statistical sampling resources
Practical Tips for Internal Investigative and Remediation Strategies

Practical Tips
• Assessment of Key Policies, Procedures and Protocols
  — Overpayment policy
  — Internal investigations policy
  — Audit protocols
  — Self-disclosure processes
  — Others
Practical Tips (Cont’d)

• Examples of Key Policy Considerations

  – **Credible Information of Potential Overpayments:** Credible Information is information that supports a reasonable belief that an Overpayment may have been received and triggers several important deadlines.
    – Who is authorized to determine whether information is “credible”?
    – Who is designated to answer questions regarding credible information of potential overpayments?
  
  – **Lookback Period:** The CMS Final Rule includes a maximum lookback period of 6 years.
    – How will the organization approach the determination of an appropriate lookback period when assessing potential overpayments?
    – For example, will there be a designated point person to help determine the appropriate lookback period when the organization is pursuing internal reviews?

---

Practical Tips (Cont’d)

• Examples of Key Policy Considerations

  – **Internal Review Deadlines:** Once Credible Information of potential overpayments has been received, a good faith investigation of such Credible Information should be pursued promptly and **absent extraordinary circumstances**, should be completed within **six months** from receipt of the Credible Information.
    – How will the organization maintain a record of its review timelines to ensure that it does not exceed the maximum six month period?
    – Who is authorized to determine whether extraordinary circumstances exist, thereby extending the six month internal review period.

  – **Threshold for Immediate Notification of Compliance, Legal and Others:** Does the policy include triggers that allow for immediate reporting obligations to Compliance, Legal and other appropriate stakeholders?
Practical Tips (Cont’d)

• Reasonable Diligence
  • Consider thoroughly documenting all important decisions regarding the investigation of potential overpayments, including whether (and when) certain information was ultimately determined to be a “credible” source of information.
  • Consider implementing specific overpayment workflows to ensure that the appropriate stakeholders (such as legal or compliance) are involved in certain key aspects of the identification, investigation, reporting, and returning of overpayments.

Practical Tips (Cont’d)

• Compliance Program Considerations
  — Can you demonstrate the effectiveness of your compliance program?
  — How does your compliance program compare to evolving CIA requirements?
  — Do you have an active risk assessment program?
  — Do you have sufficient resources?
Practical Tips (Cont’d)

• Investigation Strategies
  – Preparing employees for government investigations and inquiries
  – *Upjohn* warnings
  – Potential need for individual counsel
  – Pressure to hold an individual accountable for the conduct
  – Insurance considerations

Practical Tips (Cont’d)

• *Don’t forget your governing body*
  • Updates on significant industry developments
  • Expectations for active oversight and involvement
  • Resources needed by the entity to meet government expectations
Q&A

Sara Kay Wheeler
King & Spalding
404-572-4685
skwheeler@kslaw.com